James T. Cross

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

3rd Party Cookies

Latest Research & Publications

An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Analysing Global Immunisation Expenditure

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

Challenges and Solutions for Budget Impact Analysis of Gene Therapies

Establishing the Economic Value of Carbon-Minimal Inhalers

The Importance of Diversity of Supply in Rare Diseases Markets

2023 OHE Annual Report to the Charity Commission

Employer Costs from Respiratory Infections

All Publications

External Expert Profile

James T. Cross

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Challenges and Opportunities for Improving Benefit-Risk Assessment of Pharmaceuticals from an Economic Perspective

Share on Mastodon